[1] Hwang S Y, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment[J]. Clin Mol Hepatol, 2025, 31(Suppl):S228-S254. [2] Zhong B Y, Fan W, Guan J J, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma[J]. Lancet Gastroenterol Hepatol, 2025, 10(4):369-386. [3] Zong S, Yang Y, Yin Z, et al. Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis[J]. Front Immunol, 2025, 16:1577614. [4] Fujita K, Takuma K, Oura K, et al. Transarterial chemoembolization for patients with hepatocellular carcinoma using miriplatin without the need for hydration[J]. Clin Transl Sci, 2025, 18(3):e70182. [5] Kuehnle R A, Tchelebi L T, Ludmir E B, et al. Meta-analysis of randomized controlled trials of external-beam radiation versus transarterial chemoembolization for hepatocellular carcinoma[J]. Cancer, 2025, 131(3):e35720. [6] Hanif H, Ali M J, Susheela A T, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma[J]. World J Gastroenterol, 2022, 28(2):216-229. [7] Wang Y Q, Wang A J, Zhang T T, et al. Association of alpha-fetoprotein and metastasis for small hepatocellular carcinoma: a propensity-matched analysis[J]. Sci Rep, 2022, 12(1):15676. [8] Norman J S, Li P J, Kotwani P, et al. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation[J]. J Hepatol, 2023, 79(6):1469-1477. [9] Liu Y, Han G, Gong J, et al. Intramolecular fluorescence resonance energy transfer strategy for accurate detection of AFP-L3% and improved diagnosis of hepatocellular carcinoma[J]. Spectrochim Acta A Mol Biomol Spectrosc, 2023, 300:122950. [10] Kudo M. Urgent global need for PIVKA-Ⅱ and AFP-L3 measurements for surveillance and management of hepatocellular carcinoma[J]. Liver Cancer, 2024, 13(2):113-118. [11] Ren T, Hou X, Zhang X, et al. Validation of combined AFP, AFP-L3, and PIVKA-Ⅱ for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients[J]. Heliyon, 2023, 9(11):e21906. [12] Barcena-Varela M, Monga S P, Lujambio A. Precision models in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2025, 22(3):191-205. [13] Singh S P, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2025, 15(2):102446. [14] Marsh T L, Parikh N D, Roberts L R, et al. A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis[J]. Gastroenterology, 2025, 168(2):316-326.e6. [15] Fang Y S, Wu Q, Zhao H C, et al. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(9):1065-1076. [16] Guan M C, Ouyang W, Liu S Y, et al. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-Ⅱ, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: a multicenter analysis[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(6):559-568. [17] Fukushima R, Harimoto N, Okuyama T, et al. New predictors of microvascular invasion for small hepatocellular carcinoma≤3 cm[J]. Int J Clin Oncol, 2024, 29(8):1182-1190. [18] Mohammadzadeh S, Mohebbi A, Abdi A, et al. Inter-reader agreement of RECIST and mRECIST criteria for assessing response to transarterial chemoembolization in hepatocellular carcinoma[J]. BMC Med Imaging, 2025, 25(1):148. [19] Kim D H, Min E J, Kim B, et al. RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab[J]. Eur Radiol, 2025, 35(2):684-694. [20] Öcal O, Schinner R, Schütte K, et al. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib[J]. Cancer Imaging, 2022, 22(1):1. |